XENE Xenon Pharmaceuticals Inc. Stock Quote

XENE [NASD]

Index	-	P/E	-	EPS (ttm)	-0.88	Insider Own	1.10%	Shs Outstand	35.00M	Perf Week	2.63%
Market Cap	577.95M	Forward P/E	-	EPS next Y	-1.27	Insider Trans	0.00%	Shs Float	32.72M	Perf Month	11.99%
Income	-27.00M	PEG	-	EPS next Q	-0.39	Inst Own	87.20%	Short Float	3.48%	Perf Quarter	52.10%
Sales	30.30M	P/S	19.07	EPS this Y	5.20%	Inst Trans	7.09%	Short Ratio	7.73	Perf Half Y	25.16%
Book/sh	4.98	P/B	3.21	EPS next Y	-47.70%	ROA	-13.60%	Target Price	23.00	Perf Year	1.98%
Cash/sh	5.27	P/C	3.03	EPS next 5Y	-	ROE	-17.40%	52W Range	7.00 - 18.45	Perf YTD	3.84%
Dividend	-	P/FCF	-	EPS past 5Y	-29.80%	ROI	-42.80%	52W High	-13.44%	Beta	1.36
Dividend %	-	Quick Ratio	11.50	Sales past 5Y	-24.80%	Gross Margin	-	52W Low	128.14%	ATR	0.99
Employees	100	Current Ratio	11.50	Sales Q/Q	88.60%	Oper. Margin	-	RSI (14)	61.64	Volatility	6.22% 7.24%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	25.70%	Profit Margin	-88.90%	Rel Volume	4.00	Prev Close	16.51
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 05 AMC	Payout	-	Avg Volume	147.38K	Price	15.97
Recom	1.20	SMA20	5.01%	SMA50	22.75%	SMA200	29.93%	Volume	589,121	Change	-3.27%

Oct-02-20

Initiated

SVB Leerink

Outperform

$22

Jul-21-20

Initiated

Needham

Buy

$22

Jun-01-20

Resumed

Jefferies

Buy

$23

Mar-25-20

Initiated

Wedbush

Outperform

$23

Jan-08-20

Initiated

William Blair

Outperform

Sep-20-19

Initiated

Guggenheim

Buy

$25

Aug-08-18

Reiterated

Stifel

Buy

$9 → $15

Mar-13-17

Initiated

Jefferies

Buy

$13

Oct-21-16

Initiated

Stifel

Buy

$18

Sep-26-16

Initiated

Guggenheim

Buy

$20

Apr-14-16

Reiterated

Jefferies

Buy

$10 → $13

Oct-30-15

Resumed

Jefferies

Buy

Dec-02-14

Initiated

Canaccord Genuity

Buy

$15

Jan-14-21 08:00AM	Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021 GlobeNewswire
Dec-07-20 04:03PM	Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at AES2020, the Virtual Annual Meeting of the American Epilepsy Society GlobeNewswire
Nov-13-20 09:00AM	Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-09-20 02:15PM	Here's What Analysts Are Forecasting For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) After Its Third-Quarter Results Simply Wall St.
Nov-07-20 12:31AM	Xenon Pharmaceuticals Inc (XENE) Q3 2020 Earnings Call Transcript Motley Fool
Nov-06-20 01:35PM	Analysts Have Just Cut Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Estimates By 18% Simply Wall St. -7.43%
Nov-05-20 06:45PM	Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Lags Revenue Estimates Zacks +5.52%
04:01PM	Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
02:45PM	Xenon Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-20 05:26PM	Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update GlobeNewswire +6.28%
Oct-08-20 08:02AM	Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE Before Year-End GlobeNewswire
08:00AM	Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy GlobeNewswire
Sep-28-20 08:02PM	Hedge Funds Are Done Buying Xenon Pharmaceuticals Inc (XENE) Insider Monkey
Sep-22-20 03:41PM	We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Easily Afford To Drive Business Growth Simply Wall St.
Aug-17-20 08:30AM	Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer GlobeNewswire
Aug-06-20 08:20PM	Xenon Pharmaceuticals (XENE) Reports Break-Even Earnings for Q2 Zacks
04:01PM	Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Aug-04-20 04:01PM	Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
Jul-30-20 04:01PM	Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update GlobeNewswire
Jul-12-20 01:31PM	Did Hedge Funds Make The Right Call On Xenon Pharmaceuticals Inc (XENE) ? Insider Monkey
Jun-17-20 04:04PM	Neurocrine Adds to Pipeline With $2 Billion Takeda Deal GuruFocus.com
Jun-08-20 02:06AM	Hedge Funds Arent Done Buying Xenon Pharmaceuticals Inc (XENE) Insider Monkey
Jun-01-20 04:20PM	Xenon Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference GlobeNewswire
11:31AM	News Flash: Analysts Just Made A Sizeable Upgrade To Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Forecasts Simply Wall St.
May-25-20 08:28AM	Earnings Beat: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts Simply Wall St.
May-22-20 10:23AM	The Xenon Pharmaceuticals (NASDAQ:XENE) Share Price Is Up 247% And Shareholders Are Boasting About It Simply Wall St. +7.43%
04:30AM	Xenon Pharmaceuticals Inc (XENE) Q1 2020 Earnings Call Transcript Motley Fool
May-21-20 05:15PM	Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:01PM	Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Xenon Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-14-20 04:01PM	Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Provide Corporate Update GlobeNewswire
Mar-31-20 08:30AM	Xenon Pharmaceuticals Provides Corporate Update in the Context of COVID-19 GlobeNewswire
Mar-28-20 12:12AM	Edited Transcript of XENE earnings conference call or presentation 9-Mar-20 8:30pm GMT Thomson Reuters StreetEvents
Mar-26-20 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-23-20 09:06AM	Does The Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Share Price Fall With The Market? Simply Wall St.
Mar-09-20 04:01PM	Xenon Pharmaceuticals Reports 2019 Financial Results and Provides Corporate Update GlobeNewswire -14.53%
02:30PM	Xenon Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-02-20 04:01PM	Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2019 Financial Results and Provide Corporate Update GlobeNewswire
Feb-14-20 11:11AM	Xenon Pharmaceuticals Announces Full Exercise and Closing of Underwriters Option to Purchase Additional Shares GlobeNewswire
Feb-06-20 11:53AM	Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan Zacks
Feb-04-20 11:44AM	What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings? Zacks
08:13AM	Top Ranked Momentum Stocks to Buy for February 4th Zacks
Feb-03-20 11:11AM	Aimmune's Palforzia Wins FDA Approval for Peanut Allergy Zacks
Jan-27-20 04:01PM	Xenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares GlobeNewswire
Jan-24-20 10:26AM	Top Ranked Momentum Stocks to Buy for January 24th Zacks
Jan-23-20 12:00PM	Are You Looking for a Top Momentum Pick? Why Xenon Pharmaceuticals (XENE) is a Great Choice Zacks -6.95%
07:24AM	The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment Benzinga
Jan-22-20 08:49PM	Xenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common Shares GlobeNewswire
04:01PM	Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares GlobeNewswire
Jan-13-20 08:30AM	Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update GlobeNewswire
Jan-10-20 08:08AM	Will Xenon Continue to Surge Higher? Zacks
Dec-11-19 11:23AM	Did Hedge Funds Drop The Ball On Xenon Pharmaceuticals Inc (XENE) ? Insider Monkey -8.81%
Dec-07-19 08:45AM	Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting GlobeNewswire
Dec-06-19 08:45AM	Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting GlobeNewswire
Dec-03-19 05:23PM	Xenon Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire +10.32%
07:59AM	The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Benzinga
Dec-02-19 07:45AM	Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update on License and Collaboration Agreement with Neurocrine Biosciences GlobeNewswire
07:30AM	Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy GlobeNewswire
Nov-21-19 09:44AM	Edited Transcript of XENE earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-15-19 08:45AM	Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-11-19 09:45AM	Is Xenon Pharmaceuticals Inc (XENE) A Good Stock To Buy? Insider Monkey
Nov-05-19 04:01PM	Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Oct-29-19 04:30PM	Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Provide Corporate Update GlobeNewswire
Oct-25-19 02:20PM	Volatility 101: Should Xenon Pharmaceuticals (NASDAQ:XENE) Shares Have Dropped 18%? Simply Wall St.
Oct-16-19 08:30AM	Encode Ideas, L.P. Announces the Initiation of Research Coverage on Xenon Pharmaceuticals Inc. Newsfile
Oct-01-19 07:21AM	Xenon Sees Hammer Chart Pattern: Time to Buy? Zacks
Sep-25-19 04:05PM	Xenon Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
11:49AM	Have Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Insiders Been Selling Their Stock? Simply Wall St.
Sep-24-19 09:36AM	Does The Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Share Price Fall With The Market? Simply Wall St.
Sep-17-19 04:05PM	Xenon Announces Appointment of Shelley McCloskey as Senior Vice President, Human Resources GlobeNewswire
Sep-09-19 04:01PM	Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexions Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain GlobeNewswire
Sep-05-19 11:22AM	Edited Transcript of XENE earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-14-19 12:51PM	Is Xenon Pharmaceuticals (NASDAQ:XENE) Using Too Much Debt? Simply Wall St.
Aug-06-19 09:33PM	Xenon Pharmaceuticals Inc. (XENE) Q2 2019 Earnings Call Transcript Motley Fool
Jul-31-19 04:01PM	Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Provide Corporate Update GlobeNewswire
Jul-09-19 11:11AM	Do Institutions Own Shares In Xenon Pharmaceuticals Inc. (NASDAQ:XENE)? Simply Wall St.
Jun-14-19 06:55PM	Hedge Funds Have Never Been This Bullish On Xenon Pharmaceuticals Inc (XENE) Insider Monkey
Jun-05-19 08:10AM	Xenon Pharmaceuticals Presents Corporate Update on Neurology-Focused Pipeline at the Jefferies 2019 Healthcare Conference GlobeNewswire
Jun-03-19 05:58PM	Edited Transcript of XENE earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-29-19 04:19PM	Xenon Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-21-19 03:18PM	Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Overpaying Its CEO? Simply Wall St. +6.03%
May-15-19 12:31PM	Xenon Pharmaceuticals Inc. (XENE) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 05:19PM	Xenon Pharmaceuticals: 1Q Earnings Snapshot Associated Press
04:01PM	Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Apr-30-19 04:01PM	Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Provide Corporate Update GlobeNewswire
Apr-24-19 04:01PM	Xenon Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference GlobeNewswire
Apr-04-19 09:00AM	Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Immense Growth Potential? Simply Wall St.
Mar-13-19 02:02AM	Edited Transcript of XENE earnings conference call or presentation 6-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-06-19 04:01PM	Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Xenon Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
07:39AM	The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split Benzinga
Feb-27-19 04:01PM	Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2018 Financial Results and Provide Corporate Update GlobeNewswire +7.42%
Feb-26-19 07:30AM	Behind the Seizure Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures PR Newswire
Jan-28-19 08:00AM	Xenon Provides Key Regulatory Updates on XEN007 and XEN1101 GlobeNewswire
Jan-18-19 12:24PM	What Kind Of Shareholder Owns Most Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock? Simply Wall St.
Jan-06-19 09:00PM	Xenon Pharmaceuticals Outlines 2019 Key Milestones GlobeNewswire
Dec-26-18 02:14PM	Eversept Partners Return, AUM, and Holdings Insider Monkey
Dec-19-18 01:54AM	Xenon Pharmaceuticals Inc (XENE): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-03-18 07:30AM	Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting GlobeNewswire
Nov-30-18 09:00AM	Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting GlobeNewswire +5.51%

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in Phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase I clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop first-in-class treatments for epilepsy. The company was founded in 1996 and is headquartered in Burnaby, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AZAB MOHAMMAD	Director	Dec 15	Option Exercise	3.76	3,086	11,603	63,733	Dec 15 04:39 PM
TARNOW MICHAEL M	Director	Oct 28	Option Exercise	3.76	10,288	38,683	80,001	Oct 29 04:27 PM
PATOU GARY	Director	Oct 28	Option Exercise	3.76	2,057	7,734	23,573	Oct 29 04:20 PM
TARNOW MICHAEL M	Director	Jun 09	Option Exercise	3.52	5,144	18,107	69,713	Jun 10 05:17 PM
ROBIN SHERRINGTON	EVP, Strategy & Innovation	Jun 01	Option Exercise	3.56	8,230	29,299	18,426	Jun 02 05:40 PM
PIMSTONE SIMON N.	CEO	Jun 01	Sale	14.43	3,000	43,290	255,186	Jun 02 04:50 PM
HOLLER FRANK A	Director	May 29	Option Exercise	3.56	3,086	10,986	122,041	Jun 02 04:54 PM
PIMSTONE SIMON N.	CEO	May 29	Sale	13.99	5,000	69,950	258,186	Jun 02 04:50 PM
PIMSTONE SIMON N.	CEO	May 26	Option Exercise	3.56	6,172	21,972	264,294	May 28 05:02 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience